BUSINESS SEGMENT INFORMATION Business Segment information (Notes)

3 Months Ended

Mar. 31, 2016

Segment Reporting Information [Line Items]

Segment Reporting Disclosure [Text Block]

BUSINESS SEGMENT INFORMATION

The following table is a summary of segment information for the three months ended March 31, 2016 and 2015. The management approach has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM.

In connection with the Acquisition, the Company changed its operating segments to align with how the CODM evaluates financial information used to allocate resources and assess performance of the Company post-Acquisition. As a result, the segment information presented in these financial statements has been conformed to present segments on this revised basis for all prior periods. Under the new organizational structure, the CODM manages the Company under two segments: LCD and CDD. LCD includes all of the legacy LabCorp business and the nutritional chemistry and food safety business, which was previously part of Covance but excludes LabCorp's legacy clinical trials testing business, which is now part of CDD. CDD includes all of Covance's legacy business and LabCorp's legacy clinical trials testing business, but excludes the nutritional chemistry and food safety business, which is now part of LCD.

Segment asset information is not presented because it is not used by the CODM at the segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses are included in general corporate expenses below. The table below represents information about the Company’s reporting segments for the three months ended March 31, 2016 and 2015:

	Three Months Ended
	March 31,
	2016			2015
Total revenues:
LCD - net revenue	$	1,590.6		$	1,472.0
CDD - net revenue	704.6			300.3
Total revenues	2,295.2			1,772.3
Operating earnings (loss):
LCD	277.0			210.4
CDD	63.0			(50.4		)
Unallocated corporate expenses	(38.1		)	(27.6		)
Total operating income	301.9			132.4
Other income (expense), net	(45.9		)	(99.9		)
Earnings before income taxes	256.0			32.5
Provision for income taxes	95.5			29.1
Net earnings	160.5			3.4
Less income attributable to noncontrolling interests	(0.3		)	(0.3		)
Net income attributable to Laboratory Corporation of America Holdings	$	160.2		$	3.1